H&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS

Size: px
Start display at page:

Download "H&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS"

Transcription

1 H&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS Each of you should have 37 new cards: 7 orange cards for antimetabolites 11 white cards for miscellaneous drugs (2 DNA synthesis inhibitors, 1 enzyme, 3 signal transduction inhibitors, 1 proteosome inhibitor, 2 antiangiogenesis agents and 2 differentiating agents) 5 purple cards for drugs that suppress immune system function 14 pink cards for drugs that stimulate immune system function and 5 pages of drug labels, which include enzyme and antigen stickers. Overall, the cards should look like this: CCS or CCNS Regimens Therapeutic Uses: Subclass DRUG NAME Enzyme/antigen PK: Toxicities: Acute: Delayed: To assemble the cards: 1. Apply the drug names to the appropriate cards: Drugs that prevent DNA synthesis (orange labels): On orange cards: 5-FLUOROURACIL (5-FU), 6-MERCAPTOPURINE, 6-THIOGUANINE, AZATHIOPRINE, CYTARABINE, GEMCITABINE, METHOTREXATE On white cards: HYDROXYUREA, PENTOSTATIN

2 Drugs that alter protein function (black labels on white cards): L-ASPARAGINASE, BORTEZOMIB, ERLOTINIB, GEFITINIB, IMATINIB Angiogenesis inhibitors (red labels): ANGIOSTATIN and THALIDOMIDE (on white cards) and BEVACIZUMAB, INTERLEUKIN 12 and INTERFERON α (on pink cards) Differentiating agents (brown labels on white cards): ARSENIC TRIOXIDE, TRETINOIN Drug that suppresses immune system function AND inhibits hormone synthesis (purple and yellow label on purple card): AMINOGLUTETHIMIDE Drugs that suppress immune system function (purple labels on purple cards): CYCLOSPORINE, DEXAMETHASONE, PREDNISONE, TACROLIMUS (FK506) Drugs that stimulate immune system function (rose labels on pink cards): INTERLEUKIN-2 (IL-2) and TUMOR NECROSIS FACTOR α Antibodies and fusion protein (pink labels on pink cards): ALEMTUZUMAB, CETUXIMAB, EDRECOLOMAB, DENILEUKIN DIFTITOX, GEMTUZUMAB, IBRITUMOMAB, RITUXIMAB, TOSITUMOMAB, TRASTUZUMAB 2. Write subclass designators onto the front of the immunosuppressor (purple) cards: Glucocorticoids: AMINOGLUTETHIMIDE, DEXAMETHASONE, PREDNISONE Antibiotics: CYCLOSPORINE, TACROLIMUS and on the fusion protein (white) card: Fusion protein: DENILEUKIN DIFTITOX 3. Put enzyme and antigen stickers on the cards as follows: DHFR: Thymidylate synthase: PNP, HGPRT: METHOTREXATE 5-FLUOROURACIL 6-MERCAPTOPURINE, 6-THIOGUANINE, AZATHIOPRINE

3 Ribonucleotide reductase: PENTOSTATIN, HYDROXYUREA 26S Proteosome BORTEZOMIB Tyrosine kinase: ERLOTINIB, GEFITINIB, IMATINIB CD52: ALEMTUZUMAB EGFR CETUXIMAB 17-1A EDECOLOMAB CD33: GEMTUZUMAB CD20: IBRITUMOMAB ***first radiolabelled antibody approved!, RITUXIMAB, TOSITUMOMAB HER2 (ErbB2): TRASTUZUMAB IL-2 receptor DENILEUKIN DIFTITOX 4. Write CCNS/CCS designations onto the appropriate cards (it's only critical for the CCS drugs, since this terminology is typically applied to the traditional antineoplastic agents, rather than the newer agents): CCNS CCS L-asparaginase Cetuximab Methotrexate Erlotinib Edrecolomab 5-Fluorouracil Imatinib Gemtuzumab 6-Mercaptopurine Gefitinib Ibritumomab 6-Thioguanine Bortezomib Rituximab Cytarabine Aminoglutethimide Tositumomab Gemcitabine Dexamethasone Trastuzumab Pentostatin Cyclosporine Angiostatin Hydroxyurea Prednisone Bevacizumab Azathioprine Tacrolimus Interleukin 12 Interleukin-2 Thalidomide Interferon α Denileukin diftitox Tumor necrosis factor α Bortezomib Alemtuzumab Arsenic trioxide 5. Write the regimen designations onto the appropriate cards: CHOP: prednisone CMF: methotrexate, 5-fluorouracil FAC: 5-fluorouracil MOPP: prednisone

4 6. I d also suggest that you write in the following therapeutic uses, since we will spend very little time on this during the lecture (this is also the order in which the drugs will be presented in lecture or in the CML module): METHOTREXATE acute lymphoblastic leukemia in children, meningeal leukemia or lymphoma, Burkitt s and other non-hodgkin s lymphomas, choriocarcinoma, breast, head and neck, ovarian and bladder cancer 5-FLUOROURACIL GI cancers, breast cancer, ovarian cancer, head and neck cancer AZATHIOPRINE acute leukemias 6-MERCAPTOPURINE acute leukemia esp. acute granulocytic leukemia 6-THIOGUANINE acute leukemia esp. acute granulocytic leukemia CYTARABINE acute granulocytic leukemia GEMCITABINE metastatic pancreatic cancer, non-small cell lung cancer PENTOSTATIN hairy cell leukemia HYDROXYUREA myeloproliferative disorders, including chronic granulocytic leukemia and essential thrombocytosis, metastatic malignant melanoma AMINOGLUTETHIMIDE breast and prostate cancer DEXAMETHASONE brain metastases, prostate cancer, multiple myeloma PREDNISONE acute leukemia, lymphomas, myeloma and other hematologic cancers, as well as in advanced breast cancer; adrenocortical carcinoma; childhood acute lymphoblastic leukemia; Hodgkin s disease CYCLOSPORINE relapsed or resistant leukemias; adjunct to BMT TACROLIMUS relapsed or resistant leukemias; adjunct to BMT INTERLEUKIN-2 metastatic renal cell carcinoma and malignant melanoma INTERFERON α α hairy cell leukemia, chronic myelogenous leukemia, malignant melanoma and Karposi s sarcoma, hemangiomas in infants (phase III clinical trials) TUMOR NECROSIS FACTOR α malignant melanoma and soft tissue sarcoma of the extremities ALEMTUZUMAB B-cell chronic lymphocytic leukemia (B-CLL) BEVACIZUMAB colon cancer CETUXIMAB advanced colorectal cancer that has metastasized GEMTUZUMAB CD33-positive acute myeloid leukemia (AML) EDRECOLOMAB colon cancer

5 RITUXIMAB CD20 positive, B-cell non-hodgkin s lymphoma TOSITUMOMAB CD20 positive, B-cell non-hodgkin s lymphoma IBRITUMOMAB CD20 positive, B-cell non-hodgkin s lymphoma TRASTUZUMAB metastatic breast cancer (tumors overexpressing the HER2 protein) EDECOLOMAB colon cancer DENILEUKIN DIFTITOX cutaneous T-cell lymphoma INTERLEUKIN 12 neuroblastoma, renal cell carcinoma, malignant melanoma, breast cancer THALIDOMIDE Kaposi s sarcoma, brain, bone and colon cancer, small cell lung cancer, multiple myeloma TREINOIN acute promyelocytic leukemia ARSENIC TRIOXIDE acute promyelocytic leukemia IMATINIB chronic myeloid leukemia, gastrointestinal stomal tumour (GIST) ERLOTINIB non-small cell lung cancer GEFITINIB non-small cell lung, bowel, stomach, ovarian, prostate and breast cancer BORTEZOMIB multiple myeloma L-ASPARAGINASE childhood acute leukemias 7. Since I suspect we ll be short of time in this lecture, I ve given you the pharmacokinetic and toxicity information in the handout. Obviously, you can transfer the info from the handout to the cards if you want. 8. Put the cards into the order that they will be introduced in the lecture (see part 6, or check your main handout; thalidomide will be last!). 9. AMINOGLUTETHIMIDE, CYCLOSPORINE, DEXAMETHASONE, PREDNISONE and TACROLIMUS will not be discussed in detail in this class, as they are more completely discussed in Dr. Regal s lectures. The cards are provided so you won t forget that these agents are also used in cancer chemotherapy!

DRUG PROPERTIES YOU NEED TO KNOW

DRUG PROPERTIES YOU NEED TO KNOW jfitzake@d.umn.edu www.d.umn.edu/~jfitzake Page 1 of 8 DRUG PROPERTIES YOU NEED TO KNOW 1. Mechanism of action a. chemical class b. resistance 2. Pharmacokinetics 3. Therapeutic uses 4. Major side effects/toxicities

More information

DRUGS YOU NEED TO KNOW

DRUGS YOU NEED TO KNOW jfitzake@d.umn.edu Page 1 of 7 DRUGS YOU NEED TO KNOW ALKYLATING AGENTS (blue cards) BUSULFAN CARMUSTINE (BCNU) CYCLOPHOSPHAMIDE DACARBAZINE LOMUSTINE (CCNU) MECHLORETHAMINE MELPHALAN THIOTEPA NATURAL

More information

DRUG PROPERTIES YOU NEED TO KNOW

DRUG PROPERTIES YOU NEED TO KNOW Dr. Janet Fitzakerley Summer 2013 Med 6541 Hematopoiesis and Host Defences jfitzake@d.umn.edu www.d.umn.edu/~jfitzake Page 1 of 11 DRUG PROPERTIES YOU NEED TO KNOW 1. Mechanism of action a. chemical class

More information

New Developments in Cancer Treatment. Dulcinea Quintana, MD

New Developments in Cancer Treatment. Dulcinea Quintana, MD New Developments in Cancer Treatment Dulcinea Quintana, MD Mortality Rates Goals of treatment 1 Cure Goal of treatment 2 Prolong life Goals of treatment 3 Improve Quality of Life Goals of treatment 4

More information

Drug-targeted therapies and Predictive Prognosis: Changing Role for the Pathologist

Drug-targeted therapies and Predictive Prognosis: Changing Role for the Pathologist Drug-targeted therapies and Predictive Prognosis: Changing Role for the Pathologist Moderator: S. Terence Dunn, Ph.D. Associate Professor, Pathology Director, Molecular Pathology Laboratory University

More information

Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December

Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December 17 2010. 32/10 Imatinib for gastrointestinal stromal tumours (unresectable/metastatic) (update on

More information

ASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER

ASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER European Medicines Agency Evaluation of Medicines for Human Use London, September 2006 Doc. Ref.: EMEA/384641/2006 ASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER The Paediatric

More information

National Cancer Drugs Fund List - Approved

National Cancer Drugs Fund List - Approved National Cancer Drugs Fund List - Approved DRUG Abiraterone Aflibercet Albumin Bound Paclitaxel Axitinib CDF INDICATION (EXCLUDING APPROVED CRITERIA ) Metastatic Prostate Cancer Metastatic Colorectal Cancer

More information

SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS

SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS (Filgrastim, Capecitabine, Imatinib, Dasatinib, Erolotinib, Sunitinib, Pazopanib, Fludarabine, Sorafenib, Crizotinib, Tretinoin, Nilotinib,

More information

University of Groningen. Health economics of targeted cancer therapies Mihajlovic, Jovan

University of Groningen. Health economics of targeted cancer therapies Mihajlovic, Jovan University of Groningen Health economics of targeted therapies Mihajlovic, Jovan IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please

More information

CancerPACT Cancer Patients Alliance for Clinical Trials

CancerPACT Cancer Patients Alliance for Clinical Trials TM CancerPACT Cancer Patients Alliance for Clinical Trials Listing of Ongoing Cancer Clinical Trials in the Salinas Valley Winter 2008 I. Solid Tumors 1. Breast p.1 2. Central Nervous System p.2 3. Gastrointestinal

More information

New Developments in Cancer Treatment. Ian Rabinowitz MD

New Developments in Cancer Treatment. Ian Rabinowitz MD New Developments in Cancer Treatment Ian Rabinowitz MD Treatment Outline Angiogenesis inhibition Targeted therapy Immunotherapy Personalization of therapy Genomics and cancer Stem cells and cancer Angiogenesis

More information

Year III Pharm D. Dr. V. Chitra

Year III Pharm D. Dr. V. Chitra Year III Pharm D. Dr. V. Chitra 50.2 Rang Etiolopathology Cell Cycle = Growth, Division 18_01_cell_cycle.jpg Characteristics of Cancer Cells The problem: Cancer cells divide rapidly (cell cycle is accelerated)

More information

Guidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients

Guidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients Guidelines on Chemotherapy-induced Nausea Vomiting in Pediatric Cancer Patients COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive Care Endorsed Guidelines. DISCLAIMER For

More information

Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center

Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center 717-544-3113 PROTOCOL NO STUDY TITLE PRINCIPAL INVESTIGATOR ECOG

More information

1 The Cancer Programs Regulation (AR 242/98) is amended by this Regulation.

1 The Cancer Programs Regulation (AR 242/98) is amended by this Regulation. Alberta Regulation 18/2005 Cancer Programs Act AMENDMENT REGULATION Filed: February 22, 2005 For information only: Made by the Minister of Health and Wellness (M.O. 9/2005) on February 17, 2005 pursuant

More information

Stratified medicine in practice: Review of predictive biomarkers in European Medicines Agency (EMA) indications

Stratified medicine in practice: Review of predictive biomarkers in European Medicines Agency (EMA) indications Stratified medicine in practice: Review of predictive biomarkers in European Medicines Agency (EMA) indications Kinga Malottki, Mousumi Biswas, Jon Deeks, Richard Riley, Charles Craddock, Lucinda Billingham

More information

TARGETED THERAPY FOR CHILDHOOD CANCERS

TARGETED THERAPY FOR CHILDHOOD CANCERS TARGETED THERAPY FOR CHILDHOOD CANCERS AZIZA SHAD, MD AMEY DISTINGUISHED PROFESSOR OF PEDIATRIC HEMATOLOGY ONCOLOGY, BLOOD AND MARROW TRANSPLANTATION LOMBARDI CANCER CENTER GEORGETOWN UNIVERSITY HOSPITAL

More information

OVERVIEW OF COMMENTS RECEIVED ON LIST OF PAEDIATRIC NEEDS ONCOLOGY I (CYTOTOXIC THERAPY)

OVERVIEW OF COMMENTS RECEIVED ON LIST OF PAEDIATRIC NEEDS ONCOLOGY I (CYTOTOXIC THERAPY) European Medicines Agency Evaluation of Medicines for Human Use London, September 2006 Doc. Ref. OVERVIEW OF COMMENTS RECEIVED ON LIST OF PAEDIATRIC NEEDS ONCOLOGY I (CYTOTOXIC THERAPY) Table 1: Organisations

More information

2008 Oncology Pharmacy Preparatory Review Course Learning Objectives

2008 Oncology Pharmacy Preparatory Review Course Learning Objectives 2008 Oncology Pharmacy Preparatory Review Course Learning Objectives Session 1 Symptom Management, Part I, II & III Teresa A. Mays, Pharm D., BCOP Director, Investigational Drug Department San Antonio,

More information

Engineering Nanomedical Systems

Engineering Nanomedical Systems BME 695 Engineering Nanomedical Systems Lecture 9 Challenges of proper drug dosing with nanodelivery systems James F. Leary, Ph.D. SVM Endowed Professor of Nanomedicine Professor of Basic Medical Sciences

More information

I. ANTIMETABOLITES. A- Antifolates (Methotrexate, Pemetrexed, and Pralatrexate)

I. ANTIMETABOLITES. A- Antifolates (Methotrexate, Pemetrexed, and Pralatrexate) I. ANTIMETABOLITES Antimetabolites are structurally related to normal cellular components. They generally interfere with the availability of normal purine or pyrimidine nucleotide precursors by inhibiting

More information

2010 Oncology Pharmacy Preparatory Review Course for Home Study Learning Objectives

2010 Oncology Pharmacy Preparatory Review Course for Home Study Learning Objectives 2010 Oncology Pharmacy Preparatory Review Course for Home Study Learning Objectives Acute Leukemia/Tumor Lysis Syndrome John M. Valgus, Pharm.D., BCOP Hematology/Oncology Specialist University of North

More information

2. Mitotic Spindle Inhibitors (modulators of tubulin polymerisation) 3. Antimetabolites (anti-folates, pyrimidine and purine analogues)

2. Mitotic Spindle Inhibitors (modulators of tubulin polymerisation) 3. Antimetabolites (anti-folates, pyrimidine and purine analogues) CANCER DRUG CLASSES The classes of drugs currently used in the cancer clinic are 1. DNA Binding Agents (intercalating and alkylating agents) 2. Mitotic Spindle Inhibitors (modulators of tubulin polymerisation)

More information

Adverse effects of anticancer drugs (Antimetabolites agents, Alkylating agents, Antimicrotubule agents, Miscellaneous agents, Immune therapies and

Adverse effects of anticancer drugs (Antimetabolites agents, Alkylating agents, Antimicrotubule agents, Miscellaneous agents, Immune therapies and 35 Adverse effects of anticancer drugs (Antimetabolites agents, Alkylating agents, Antimicrotubule agents, Miscellaneous agents, Immune therapies and Biologically directed therapies ) 1 1- Nausea and vomiting

More information

World Health Organization: Essential Medicines and Devices for Cancer:

World Health Organization: Essential Medicines and Devices for Cancer: World Health Organization: Essential Medicines and Devices for Cancer: Principles, Methodologies, and Outcomes Lawrence N. Shulman, MD Abramson Cancer Center, University of Pennsylvania Partners In Health

More information

Azacitidine Vidaza Non-transplant myelodysplastic syndrome Funded Funded Funded Funded Funded Funded Not Funded

Azacitidine Vidaza Non-transplant myelodysplastic syndrome Funded Funded Funded Funded Funded Funded Not Funded Provincial Fundin Summary The interim Joint Oncoloy Dru Review (ijodr) was the precursor oncoloy dru review process prior to pcodr, which provided evidence-based recommendation for cancer treatments from

More information

Essentials. Oncology Practise Essentials. Oncology Basics. Tutorial 2. Cancer Chemotherapy

Essentials. Oncology Practise Essentials. Oncology Basics. Tutorial 2. Cancer Chemotherapy Practise Practise This tutorial introduces you to the history, goals of therapy, classification, and clinical uses of chemotherapy. It also reviews some of the barriers to successful therapy. Goals and

More information

Curable cancers: Progress in Oncology. Prof.Dilip Kumar Dhar Princicipal & Professor of Medicine MH Samorita Hospital & Medical College, Dhaka.

Curable cancers: Progress in Oncology. Prof.Dilip Kumar Dhar Princicipal & Professor of Medicine MH Samorita Hospital & Medical College, Dhaka. Curable cancers: Progress in Oncology Prof.Dilip Kumar Dhar Princicipal & Professor of Medicine MH Samorita Hospital & Medical College, Dhaka. Introduction Cancer is one of the leading causes of morbidity

More information

Macmillan Publications

Macmillan Publications S1 S2 S3 S3 S3 S4 S5 S6 S7 S8 S8 S9 S10 S11 S11 S12 S13 S14 S15 S17 S18 S19 Bladder Cancer: Non-Invasive, Invasive and Advanced Bone Cancer: Primary, Secondary Colon Cancer, Anal Cancer, Rectal Cancer

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Index Note: Page numbers of article titles are in boldface type. A Abdominal drainage, after hepatic resection, 159 160 Ablation, radiofrequency, for hepatocellular carcinoma, 160 161 Adenocarcinoma, pancreatic.

More information

BLOOD AND LYMPH CANCERS

BLOOD AND LYMPH CANCERS BLOOD AND LYMPH CANCERS 2 Blood and Lymph Cancers Highlights from the 2009 Annual Meeting of the American Society of Clinical Oncology Edited by Kenneth C. Anderson, MD Harvard Medical School and Dana-Farber

More information

NOSCAN CLINICAL MANAGEMENT GUIDELINE (CMG) AND NOSCAN CHEMOTHERAPY REVIEW (NCR) STATUS DOCUMENT May Status (G / A / R) Status (G / A / R)

NOSCAN CLINICAL MANAGEMENT GUIDELINE (CMG) AND NOSCAN CHEMOTHERAPY REVIEW (NCR) STATUS DOCUMENT May Status (G / A / R) Status (G / A / R) Item 18-13c NOSCAN CLINICAL MANAGEMENT GUIDELINE (CMG) AND NOSCAN CHEMOTHERAPY REVIEW (NCR) STATUS DOCUMENT May 2013 BREAST CANCER MCN: Breast Disease: Breast Document ready to circulate lead to be discussed

More information

Summary of Research and Writing Activities in Oncology

Summary of Research and Writing Activities in Oncology Summary of Research and Writing Activities in Oncology Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Manuscripts, Posters,

More information

Facts LEUKEMIA LYMPHOMA MYELOMA

Facts LEUKEMIA LYMPHOMA MYELOMA Facts 2009-2010 Table of Contents Figures 1 Executive Summary 3 About Blood Cancer Therapy Drug and Radiation Therapy Stem Cell Transplantation Quality of Life Survivorship 7 Leukemia Living with Leukemia

More information

CancerPACT Cancer Patients Alliance for Clinical Trials

CancerPACT Cancer Patients Alliance for Clinical Trials TM CancerPACT Cancer Patients Alliance for Clinical Trials Listing of Cancer Clinical Trials in the Salinas Valley Summer 2008 I. Solid Tumors 1. Breast p.1 2. Central Nervous System p.3 3. Gastrointestinal

More information

New Oncology Drugs: Nadeem Ikhlaque, M.D Subtitle Would Go Here

New Oncology Drugs: Nadeem Ikhlaque, M.D Subtitle Would Go Here New Oncology Drugs: A PowerPoint Brief Primer Cover Title Nadeem Ikhlaque, M.D 05.19.2017 Subtitle Would Go Here Learning Objectives List novel chemotherapies and the indications of these newer agents

More information

An introduction to the Essential Medicines concept: balancing innovation with public health priorities

An introduction to the Essential Medicines concept: balancing innovation with public health priorities An introduction to the Essential Medicines concept: balancing innovation with public health priorities World Oncology Forum Lugano 20 October 2017 Nicola Magrini Secretary, WHO Expert Committee on the

More information

Introduction to Targeted Therapy

Introduction to Targeted Therapy Introduction to Targeted Therapy Cancer remains the second leading cause of death in the United States, despite the significant advances in cancer therapy made over the past several decades. Many factors

More information

Targeted Therapy Vijay Narang

Targeted Therapy Vijay Narang 25 Volume 1, Issue 1, January 2013, Online: Targeted Therapy Vijay Narang ABSTRACT This is a review on targeted therapy that blocks the growth and spread of cancer by interfering with specific molecules

More information

Trial no. Status Phase Treatment Pre-conditioning Primary endpoints Secondary endpoints Diagnosis Sponsor

Trial no. Status Phase Treatment Pre-conditioning Primary endpoints Secondary endpoints Diagnosis Sponsor Supplemental table 1. Overview of recent clinical phase I and II trials assessing the safety and efficacy of TCR-modified T cells in cancer patients as registered at clinicaltrials.gov by September 1,

More information

N. Ireland Cancer Trials Centre/ N. Ireland Cancer Trials Network Trials Open to Recruitment June 2013

N. Ireland Cancer Trials Centre/ N. Ireland Cancer Trials Network Trials Open to Recruitment June 2013 N. Ireland Cancer Trials Centre/ N. Ireland Cancer Trials Network Trials Open to Recruitment June 2013 Bladder HABIO Haematuria Biomarker Study Bowel Cancer NSCCG National Study Of Colorectal Cancer Genetics

More information

TUMOR M ARKERS MARKERS

TUMOR M ARKERS MARKERS TUMOR MARKERS M.Shekarabi IUMS Definition Many cancers are associated with the abnormal production of some molecules l which h can be measured in plasma. These molecules are known as tumor markers. A good

More information

Biological Therapies for Cancer: Questions and Answers

Biological Therapies for Cancer: Questions and Answers Biological Therapies for Cancer: Questions and Answers Key Points Biological therapies use the body s immune system to fight cancer or to lessen the side effects that may be caused by some cancer treatments

More information

Treatment results in ALL

Treatment results in ALL Treatment results in ALL Adults Complete remission (CR) 80-85% Leukemia-free survival (LFS) 30-40% Children Complete remission (CR) 95-99% Leukemia-free survival (LFS) 70-80% Combination chemotherapy in

More information

Oncology Basics. Essentials. Hormonal/Endocrine Therapy, Immunotherapy and Targeted Therapy. Tutorial 4. Oncology Practise Essentials

Oncology Basics. Essentials. Hormonal/Endocrine Therapy, Immunotherapy and Targeted Therapy. Tutorial 4. Oncology Practise Essentials Part 2: Pharmacology of Cancer Chemotherapy Immunotherapy and Targeted Therapy The pharmacology of the large family of anticancer drugs is the subject of this tutorial. It will give you the background

More information

Cancer Genetics. What is Cancer? Cancer Classification. Medical Genetics. Uncontrolled growth of cells. Not all tumors are cancerous

Cancer Genetics. What is Cancer? Cancer Classification. Medical Genetics. Uncontrolled growth of cells. Not all tumors are cancerous Session8 Medical Genetics Cancer Genetics J avad Jamshidi F a s a U n i v e r s i t y o f M e d i c a l S c i e n c e s, N o v e m b e r 2 0 1 7 What is Cancer? Uncontrolled growth of cells Not all tumors

More information

Chemotherapy Teaching Points

Chemotherapy Teaching Points Chemotherapy Teaching Points 1. Antimetabolites - These drugs are analogs of vital co-factors in DNA or RNA synthesis. They competitively inhibit DNA or RNA production, or are directly incorporated into

More information

Tumor Markers & Cytopathology

Tumor Markers & Cytopathology Tumor Markers & Cytopathology Objectives: After learning, student should be able to 1. Describe the basic concepts of tumor markers and Asst. Prof. Prasit Suwannalert, Ph.D. (Email: prasit.suw@mahidol.ac.th)

More information

Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making

Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making November 20, 2014 Capturing Value in Next Generation Sequencing Symposium Douglas Johnson MD, MSCI Vanderbilt-Ingram

More information

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION SUPPLEMENTARY NFORMATON n format provided by Melero et al. (AUGUST 2015) Supplementary nformation S3 Combinations including two or more immunotherapy agents based on PD-1/PD-L1 blockade. (Source: https://clinicaltrials.gov/

More information

1 Introduction. 1.1 Cancer. Introduction

1 Introduction. 1.1 Cancer. Introduction Introduction 1 1.1 Cancer 1 Introduction Cancer is the most precarious disease characterized by uncontrolled proliferation of cells without any physiological demands of the organism. Cancer may be defined

More information

CANCER IMMUNOTHERAPY: A REVIEW

CANCER IMMUNOTHERAPY: A REVIEW SUMMARY CANCER IMMUNOTHERAPY: A REVIEW Nguyen Thi Kim Tran 1 ; Nguyen Thanh Minh 2 ; Jake Chen 2 The Nobel Prize in Physiology or Medicine signifies that cancer immunotherapy is becoming the most promising

More information

Protocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy

Protocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy Last Updated 22-Feb-18 Date of last update Protocol Number Tumour Group Protocol Name on NCCP website 22/02/2018 221 Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy 249 Gynaecology Intrathecal

More information

CLIC Sargent Eligibility Criteria

CLIC Sargent Eligibility Criteria 1 Eligibility Criteria DOCUMENT GOVERNANCE: Eligibility criteria Produced by J. Hawkins & Grants Team Sponsored by Dara de Burca Version Approval by Executive Team 10 th June 2014 Board of Trustees 3 rd

More information

West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting

West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting Definitions Acute nausea and vomiting Delayed nausea and vomiting Anticipatory nausea and vomiting Initial

More information

Peking University People's Hospital, Peking University Institute of Hematology

Peking University People's Hospital, Peking University Institute of Hematology Qian Jiang, M.D. Peking University People's Hospital, Peking University Institute of Hematology No. 11 Xizhimen South Street, Beijing, 100044, China. Phone number: 86-10-66583802 Mobile: 86-13611115100

More information

Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249

Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249 Last updated Feb 9, 2018 Revision due Protocol Name on NCCP website Tumour Group Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249 Two Day Etoposide CISplatin

More information

Intron A. Intron A (interferon alfa-2b) Description

Intron A. Intron A (interferon alfa-2b) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Intron A Page: 1 of 6 Last Review Date: June 19, 2015 Intron A Description Intron A (interferon

More information

Product Visual Guide

Product Visual Guide Product Visual Guide Teamwork A team with an unflinching faith in one another is one of our core strength. Excellence Achieving excellence is not the end result, we begin with excelling in any endeavor.

More information

Genomics Up Close And Personal: What Are The Implications For Cancer Nursing? Candy Cooley Head of Education

Genomics Up Close And Personal: What Are The Implications For Cancer Nursing? Candy Cooley Head of Education Genomics Up Close And Personal: What Are The Implications For Cancer Nursing? Candy Cooley Head of Education Aims of this session Understand how genomic information will change your clinical practice Remind

More information

*Combination therapy: *Cancer drugs are divided into groups: I) DNA binding agents (Intercalating and Alkylating agents) 2 types: Doxorubicin

*Combination therapy: *Cancer drugs are divided into groups: I) DNA binding agents (Intercalating and Alkylating agents) 2 types: Doxorubicin *Combination therapy: - Cancer is heterogeneous, and resistant anticancer drugs are common, so combination of drugs together is needed in order to attack cancer. *Cancer drugs are divided into groups:

More information

Lecture 3: Antimetabolites cell cycle specific (S-phase) 1. Folate analogs

Lecture 3: Antimetabolites cell cycle specific (S-phase) 1. Folate analogs Lecture 3: Antimetabolites cell cycle specific (S-phase) All the antimetabolites mimic endogenous molecules. They trick enzymes involved in the synthesis of DNA, and instead of metabolizing the proper

More information

Cell, Volume 141. Supplemental Information Cell Signaling by Receptor Tyrosine Kinases Mark A. Lemmon and Joseph Schlessinger

Cell, Volume 141. Supplemental Information Cell Signaling by Receptor Tyrosine Kinases Mark A. Lemmon and Joseph Schlessinger Cell, Volume 141 Supplemental Information Cell Signaling by Receptor Tyrosine Kinases Mark A. Lemmon and Joseph Schlessinger Figure S1. RTK Mutations in Diseases Locations of gain-of-function (green arrows)

More information

America, Hershey, PA Australia, Melbourne, VIC Europe, Munich

America, Hershey, PA Australia, Melbourne, VIC Europe, Munich America, Hershey, PA Australia, Melbourne, VIC Europe, Munich info@vivopharm.com www.vivopharm.com Bladder MB-9-luc 2 Mouse urinary bladder carcinoma yes yes yes C57BL/6 2 Bone UMR-106 Rat osteosarcoma

More information

Index. neurosurgery.theclinics.com. Note: Page numbers of article titles are in boldface type.

Index. neurosurgery.theclinics.com. Note: Page numbers of article titles are in boldface type. Index Note: Page numbers of article titles are in boldface type. A A Complimentary Trial of an Immunotherapy Vaccine Against Tumor-specific EGFRvIII (ACTIVATE), 90 91 Active immunotherapy, 5 8, 96. See

More information

6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017

6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017 Primary Care Focus Symposium July 1, 2017 Grace Wang MD I do not have any relevant financial relationships to disclose at this time TARGETING THE TARGETS IN 2017 What are

More information

Anti-cancer drugs. Introduction : Body : 1) Alkylating Agents

Anti-cancer drugs. Introduction : Body : 1) Alkylating Agents Anti-cancer drugs Introduction : In this journal I will try to explain what is anti-cancer agents, how they work, how can they inhibit the growth of tumor and what is the advantages and disadvantages of

More information

Oncology Take Home Messages. The Leukemias. CLL - Indications for Therapy. Chronic Lymphocytic Leukemia. Genetic Aberrations and Survival

Oncology Take Home Messages. The Leukemias. CLL - Indications for Therapy. Chronic Lymphocytic Leukemia. Genetic Aberrations and Survival Oncology Take Home Messages Ann S. LaCasce, MD Dana-Farber Cancer Institute Brigham and Women s Hospital The Leukemias Disclosures: No relevant conflicts of interest to declare Chronic Lymphocytic Leukemia

More information

What is a hematological malignancy? Hematology and Hematologic Malignancies. Etiology of hematological malignancies. Leukemias

What is a hematological malignancy? Hematology and Hematologic Malignancies. Etiology of hematological malignancies. Leukemias Hematology and Hematologic Malignancies Cancer of the formed elements of the blood What is a hematological malignancy? A hematologic malignancy is a malignancy (or cancer) of any of the formed elements

More information

Checkpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015

Checkpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015 Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib

More information

Targeted Medicine and Molecular Therapeutics. Angus McIntyre, M.D. Medical Oncologist, Addison Gilbert Hospital and Beverly Hospital October 6, 2009

Targeted Medicine and Molecular Therapeutics. Angus McIntyre, M.D. Medical Oncologist, Addison Gilbert Hospital and Beverly Hospital October 6, 2009 Targeted Medicine and Molecular Therapeutics Angus McIntyre, M.D. Medical Oncologist, Addison Gilbert Hospital and Beverly Hospital October 6, 2009 Approaches to Cancer Prevention Screening and early diagnosis

More information

NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT

NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT The NCIC CTG DSMC reviewed the following trials with respect to safety, trial conduct, including

More information

through the cell cycle. However, how we administer drugs also depends on the combinations that we give and the doses that we give.

through the cell cycle. However, how we administer drugs also depends on the combinations that we give and the doses that we give. Hello and welcome to this lecture. My name is Hillary Prescott. I am a Clinical Pharmacy Specialist at The University of Texas MD Anderson Cancer Center. My colleague, Jeff Bryan and I have prepared this

More information

PRELIMINARY PROGRAM MAY 31 - JUNE 4, 2019

PRELIMINARY PROGRAM MAY 31 - JUNE 4, 2019 MONDAY, JUNE 3, 2019 7:30 AM - 9:15 AM HIGHLIGHTS OF THE DAY 8:00 AM - 9:00 AM S 8:00 AM - 9:15 AM S S 8:00 AM - 11:00 AM S Highlights of the Day Session II Bringing New and Innovative Glioblastoma Treatments

More information

Intron A. Intron A (interferon alfa-2b) Description

Intron A. Intron A (interferon alfa-2b) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.07 Subject: Intron A Page: 1 of 6 Last Review Date: June 22, 2018 Intron A Description Intron A (interferon

More information

Standard Regimens for Haematology

Standard Regimens for Haematology Regimens for Haematology ChlVPP Chlorambucil 6mg/m 2 PO D1 to 14 Vinblastine 6mg/m 2 (max 10mg) IV on D1 & 8 Procarbazine 100mg/m 2 PO on D1 to 14 Prednisolone 40mg PO D1 to 14 ABVD Doxorubicin 25mg/m

More information

NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT

NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT The NCIC CTG DSMC reviewed the following trials with respect to safety, trial conduct, including accrual, and

More information

Avastin (bevacizumab) DRUG.00028, CG-DRUG-68

Avastin (bevacizumab) DRUG.00028, CG-DRUG-68 Avastin (bevacizumab) DRUG.00028, CG-DRUG-68 Override(s) Prior Authorization Approval Duration 1 year Medications Avastin (bevacizumab) APPROVAL CRITERIA Requests for Avastin (bevacizumab) may be approved

More information

Immunosuppressants. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Immunosuppressants. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Immunosuppressants Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Immunosuppressive Agents Very useful in minimizing the occurrence of exaggerated or inappropriate

More information

Bihong Zhao, M.D, Ph.D Department of Pathology

Bihong Zhao, M.D, Ph.D Department of Pathology Bihong Zhao, M.D, Ph.D Department of Pathology 04-28-2009 Is tumor self or non-self? How are tumor antigens generated? What are they? How does immune system respond? Introduction Tumor Antigens/Categories

More information

Tumour Markers. For these reasons, only a handful of tumour markers are commonly used by most doctors.

Tumour Markers. For these reasons, only a handful of tumour markers are commonly used by most doctors. Tumour Markers What are Tumour Markers? Tumour markers are substances that can be found in the body when cancer is present. They are usually found in the blood or urine. They can be products of cancer

More information

Cancer Chemotherapy. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan December 2018

Cancer Chemotherapy. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan December 2018 Cancer Chemotherapy Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan December 2018 Modalities of Cancer Chemotherapy Curative: Only in 10-15% of cases. In certain disseminated

More information

Cancer drug approvals for paediatric indications (n=43)

Cancer drug approvals for paediatric indications (n=43) Appendix: Supplementary material [posted as supplied by author] Figure A. Identification of cohort of drugs Total number of antineoplastic and immunomodulating products approved by the EMA up to 31 December

More information

SCI. SickKids-Caribbean Initiative Enhancing Capacity for Care in Paediatric Cancer and Blood Disorders

SCI. SickKids-Caribbean Initiative Enhancing Capacity for Care in Paediatric Cancer and Blood Disorders 1.0 Introduction The (SCI) is a not-for-profit collaboration between the Hospital for Sick Children (SickKids), Toronto, Canada, and seven Caribbean health care institutions across six countries that strive

More information

CancerPACT Cancer Patients Alliance for Clinical Trials

CancerPACT Cancer Patients Alliance for Clinical Trials TM CancerPACT Cancer Patients Alliance for Clinical Trials Listing of Ongoing Cancer Clinical Trials in the Sacramento Area Winter 2008 I. Solid Tumors 1. Breast p.1 2. Central Nervous System p.2 3. Gastrointestinal

More information

Docetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative.

Docetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative. Docetaxel Class: Antineoplastic agent, Antimicrotubular, Taxane derivative. Indications: -Breast cancer: -Non small cell lung cancer -Prostate cancer -Gastric adenocarcinoma _Head and neck cancer Unlabeled

More information

BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY

BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Cancer is a group of more than 100 different diseases that are characterized by uncontrolled cellular growth,

More information

Cancer Chemotherapy. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan December 2018

Cancer Chemotherapy. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan December 2018 Cancer Chemotherapy Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan December 2018 االدوية Polyfunctional Alkylating Agents االستخالبية متعددة الوظائف Not cell cycle-specific.

More information

Answer ALL questions. For each question, there is ONE correct answer. Use the answer grid provided for ALL your answers.

Answer ALL questions. For each question, there is ONE correct answer. Use the answer grid provided for ALL your answers. UNIVERSITY OF EAST ANGLIA School of Pharmacy Main Series UG Examination 2013-2014 CLINICAL THERAPEUTICS 8: ONCOLOGY PHA-MHCY Time allowed: 2 hours Part ONE Answer ALL questions. For each question, there

More information

Cancer-Drug Associations: A Complex System

Cancer-Drug Associations: A Complex System Cancer-Drug Associations: A Complex System Ertugrul Dalkic 1,2,3, Xuewei Wang 1,4, Neil Wright 1,5, Christina Chan 1,2,3,4,6,7 * 1 Center for Systems Biology, Michigan State University, East Lansing, Michigan,

More information

Outcomes Report: Accountability Measures and Quality Improvements

Outcomes Report: Accountability Measures and Quality Improvements Outcomes Report: Accountability Measures and Quality Improvements The FH Memorial Medical Center s Cancer Committee ensures that patients with cancer are treated according to the nationally accepted measures.

More information

MEDICAL NECESSITY GUIDELINE

MEDICAL NECESSITY GUIDELINE PAGE: 1 of 10 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted

More information

Breast Cancer: Who Gets It? Who Survives? The Latest Information

Breast Cancer: Who Gets It? Who Survives? The Latest Information Breast Cancer: Who Gets It? Who Survives? The Latest Information James J. Stark, MD, FACP Medical Director, Cancer Program and Director of Palliative Care Maryview Medical Center Professor of Medicine

More information

Table E1. Standardized Mortality Ratios for Total and Specific Causes of Death Parameter Radiologists Psychiatrists No. of Deaths

Table E1. Standardized Mortality Ratios for Total and Specific Causes of Death Parameter Radiologists Psychiatrists No. of Deaths RSNA, 2016 10.1148/radiol.2016152472 Table E1. Standardized Mortality Ratios for Total and Specific Causes of Death Parameter Radiologists Psychiatrists No. of Deaths Observed/Expected No. of Deaths Observed/Expected

More information

Proposing Trastuzumab as an Essential Medicine to Treat Cancer: Insight on Methodologies, Processes and Outcomes. Lorenzo Moja

Proposing Trastuzumab as an Essential Medicine to Treat Cancer: Insight on Methodologies, Processes and Outcomes. Lorenzo Moja Proposing Trastuzumab as an Essential Medicine to Treat Cancer: Insight on Methodologies, Processes and Outcomes Lorenzo Moja Essential Medicines List Secretariat Essential Medicines and Health Products

More information

CLINICAL MEDICAL POLICY

CLINICAL MEDICAL POLICY CLINICAL MEDICAL POLICY Policy Name: Rituxan (rituximab) Policy Number: MP-031-MD-DE Responsible Department(s): Medical Management; Clinical Pharmacy Provider Notice Date: 10/01/2017 Issue Date: 11/01/2017

More information

Directorate General of Health Services Office of Drugs Controller General (India) (Biological Division)

Directorate General of Health Services Office of Drugs Controller General (India) (Biological Division) Directorate General of Health Services Office of Drugs Controller General (India) (Biological Division) List of r-dna drug products approved in the country (Form 45 and 45A) from 1 st Jan 2015 to 30 th

More information

Haematology, Oncology and Palliative Care Directorate.

Haematology, Oncology and Palliative Care Directorate. Anticancer Treatment for Administration on the Somerset Mobile Chemotherapy Unit The table below details the suitability of different types of anticancer treatment for administration on the Somerset Mobile

More information

COST CONSIDERATIONS Union for International Cancer Control 2014 Review of Cancer Medicines on the WHO List of Essential Medicines!!!!!!!!!

COST CONSIDERATIONS Union for International Cancer Control 2014 Review of Cancer Medicines on the WHO List of Essential Medicines!!!!!!!!! UICCEMLCostingScenarios BackoftheEnvelope Calculations PreparedforWorkingGroupSession:19621November2014,Geneva MethodsSummary We have chosen a conservative approach, calculating cost per vial. We have

More information